Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001217606 | SCV001389452 | uncertain significance | Nemaline myopathy 2 | 2022-03-23 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with NEB-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 946695). This variant is present in population databases (rs377602828, gnomAD 0.002%). This sequence change replaces tryptophan, which is neutral and slightly polar, with cysteine, which is neutral and slightly polar, at codon 2596 of the NEB protein (p.Trp2596Cys). |
Natera, |
RCV001217606 | SCV002079645 | uncertain significance | Nemaline myopathy 2 | 2020-11-30 | no assertion criteria provided | clinical testing |